Prospective, open-label, noncomparative, multicenter study to evaluate the efficacy and safety of ciprofloxacin extended release (Cipro XR) 1000 mg tablets given once daily for 7 to 14 days in the treatment of patients 18 years or older with complicated urinary tract infections caused by Pseudomonas aeruginosa and other common uropathogens

Trial Profile

Prospective, open-label, noncomparative, multicenter study to evaluate the efficacy and safety of ciprofloxacin extended release (Cipro XR) 1000 mg tablets given once daily for 7 to 14 days in the treatment of patients 18 years or older with complicated urinary tract infections caused by Pseudomonas aeruginosa and other common uropathogens

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2015

At a glance

  • Drugs Ciprofloxacin (Primary)
  • Indications Pseudomonal infections; Urinary tract infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 30 Jun 2009 Actual end date (Sep 2005) added as reported by ClinicalTrials.gov.
    • 30 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top